Stock Analysts

Cara (CARA) Up on IDMC’s Recommendation to Continue Trial

Shares of clinical-stage biopharmaceutical Cara Therapeutics, Inc . CARA surged after the company announced that its phase III trial on lead candidate Korsuva (difelikefalin) can continue as planned without any changes in enrollment, based on the recommendation of the Independent Data Monitoring Committee (IDMC). […]